Table 2.
Univariate and multivariate analyses of factors associated with pathologic Gleason score downgrade in patients with biopsy Gleason scores 8–10.
| Variable | Univariate | Multivariate | ||
|---|---|---|---|---|
| OR (95% CI) | p Value | OR (95% CI) | p Value | |
| Age, year | 0.995 (0.975–1.015) | 0.592 | ||
| BMI, kg/m2 | 1.013 (0.964–1.064) | 0.607 | ||
| Prostate volume, mL | 0.996 (0.986–1.005) | 0.367 | ||
| PSA level, ng/mL | ||||
| <10 | 1 (Ref) | 1 (Ref) | ||
| ≥10 | 0.476 (0.359–0.630) | <0.001 | 0.606 (0.438–0.840) | 0.003 |
| PSA density | 0.679 (0.540–0.854) | 0.001 | 0.973 (0.799–1.185) | 0.783 |
| Gleason score | ||||
| 8 | 1 (Ref) | 1 (Ref) | ||
| ≥9 | 0.303 (0.213–0.432) | <0.001 | 0.342 (0.238–0.493) | <0.001 |
| Clinical stage according to MRI | ||||
| cT2 | 1 (Ref) | 1 (Ref) | ||
| cT3a | 0.743 (0.547–1.008) | 0.056 | 0.816 (0.592–1.123) | 0.211 |
| ≥cT3b | 0.219 (0.139–0.346) | <0.001 | 0.284 (0.176–0.458) | <0.001 |
OR, odds ratio; CI, confidence interval; Ref, reference value; BMI, body mass index; PSA, prostate-specific antigen; MRI, magnetic resonance imaging.